Cline Scientific AB announces, in accordance with Nasdaq First North s regulations, that the company cannot determine with certainty that there is sufficient working capital for the Company s needs. | May 22, 2023
Today, May 22, 2023, Cline Scientific AB (the "Company") disclosed a press
release with information that the Company cannot assure that it has working
capital for three months. The rules of Nasdaq First
Cline Scientific, a Swedish life science company developing a novel regenerative medicine, and NecstGen, a CDMO and centre of excellence for Cell and Gene Therapy, have signed a Letter of Intent to develop and manufacture clinical batches of Cline’s cell therapy for cartilage repair, StemCART. Through this .